Hospital-acquired and Ventilator-Associated Pneumonia
Key Points
Key Points
All-cause mortality associated with VAP has been reported to range from 20%–50%.
Serious complications from HAP occur in approximately 50% of patients.
Diagnosis
...Diagnos...
...ctors for Multidrug-Resistant Pathog...
...Microbiologic Meth...
ATS and IDSA suggest noninvasive sampling...
...ling with semiquantitative cultures is...
...nd IDSA suggest that patients with suspe...
...Bio...
...h suspected HAP/VAP, ATS and IDSA re...
...r patients with suspected HAP/VAP, ATS and IDSA...
...ts with suspected HAP/VAP, ATS and ID...
...nts with suspected HAP/VAP, ATS and I...
Treatment
...Treatm...
...Initia...
...tients with ventilator-associated t...
...and IDSA recommend that all hospita...
...TS and IDSA recommend that empiric treatment reg...
...s with suspected VAP, ATS and IDSA...
...d IDSA suggest including an agent active agai...
...IDSA suggest including an agent ac...
...verage for MRSA is indicated, ATS and IDSA recomme...
When empiric treatment that includes...
...suggest prescribing two antipseudo...
...d IDSA suggest prescribing one antibioti...
...ts with suspected VAP, ATS and IDSA suggest...
...n patients with suspected VAP, ATS and IDSA sug...
...d IDSA recommend that empiric antibiotic r...
...d IDSA recommend that all hospitals regularly...
...patients being treated empirically for HAP, A...
...tients with HAP who are being treated empiri...
...with HAP who require empiric coverage for MRSA, A...
...ts with HAP who are being treated empirically a...
...patients with HAP who are being treated e...
...h HAP who are being treated empirically...
...or patients with HAP who are being treat...
...Optimization...
...or patients with HAP/VAP, ATS and IDSA sug...
...Inhaled...
...atients with VAP due to Gram-negative...
Pathogen-Spe...
...nd IDSA recommend that MRSAHAP/VAP be treated wit...
...ents with HAP/VAP due to P. aeruginosa, ATS and I...
...with HAP/VAP due to P. aeruginosa, A...
...tients with HAP/VAP due to P. aeruginosa who are n...
...ients with HAP/VAP due to P. aeruginosa who...
...ts with HAP/VAP due to P. aeruginosa, ATS...
...tients with HAP/VAP due to extended...
...n patients with HAP/VAP caused by Acinetobacter sp...
...HAP/VAP caused by Acinetobacter species...
...S and IDSA suggest adjunctive inhaled colistin...
...th HAP/VAP caused by Acinetobacter spec...
...ts with HAP/VAP caused by Acinetobact...
...nts with HAP/VAP caused by a carbap...
...ATS and IDSA suggest adjunctive in...
...ith VAP, ATS and IDSA recommend a 7-da...
...th HAP, ATS and IDSA recommend a 7...
...tients with HAP/VAP, ATS and IDSA suggest that an...
...ents with HAP/VAP, ATS and IDSA sugg...
...with suspected HAP/VAP, ATS and IDSA sugge...
Table 2. Recommended Initial Empir...
...le 3. Empiric Treatment Options for Suspected MR...